Familial hypercholesterolemia (FH) is caused by mutations in the low density lipoprotein receptor (LDLR) gene. To study the impact of mutations affecting the hydrophobic transmembrane domain of the LDLR, each of the 22 amino acids of the transmembrane domain was individually mutated to arginine. The more centrally in the transmembrane domain an arginine was located, the lower amounts of the 120 kDa precursor LDLR in the endoplasmic reticulum were observed. This led to lower amounts of the 160 kDa mature LDLR on the cell surface. For the mutants V797R-LDLR, L798R-LDLR and L799R-LDLR a proportion of full-length receptors including the transmembrane and cytoplasmic domains, was secreted into the endoplasmic reticulum lumen to appear in the culture medium. When the transmembrane domain of the epidermal growth factor receptor (EGFR) was replaced by that of the mutant L799R-LDLR, similar effects were observed for the EGFR as for L799R-LDLR. Introducing arginines in the transmembrane domain of the LDLR also affected metalloproteinase cleavage of the ectodomain and c-secretase cleavage within the transmembrane domain. The most likely explanation for the low amounts of the 120 kDa precursor is that a basic residue in the hydrophobic transmembrane domain prevents the mutant LDLR from being inserted in the endoplasmic reticulum membrane from the Sec61 translocon complex. As a consequence, quality control systems could be activated. However, our data indicate that proteasomal degradation, lysosomal degradation, autophagy or ectodomain cleavage were not the underlying mechanism for degradation of these mutant LDLRs.
Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant disease caused by mutations in the low density lipoprotein receptor (LDLR) gene which lead to defective cell-surface LDLRs (1) . Since these mutant LDLRs are defective in clearing cholesterol-rich low density lipoprotein (LDL) from plasma, patients with FH have increased plasma levels of LDL cholesterol and total serum cholesterol. Those who are FH heterozygotes typically have total serum cholesterol levels in the range of 8-15 mmol/l, and those who are FH homozygotes have total serum cholesterol levels above 20 mmol/l (1). Since hypercholesterolemia is a major risk factor for coronary heart disease, patients with FH have an increased risk of contracting premature coronary heart disease (1) .
The LDLR has five structural domains (2) . These are the N-terminal ligand-binding domain, a domain with a high degree of homology with the precursor for the epidermal growth factor (EGF), a domain enriched in O-linked sugars, a transmembrane domain and a cytoplasmic domain (2) . During transport through the Golgi apparatus, the LDLR undergoes modifications of sugars which make the apparent molecular weight increase from 120 to 160 kDa (3) . The mature 160 kDa LDLR is subsequently inserted in the cell membrane were it is concentrated in clathrin-coated pits (4) .
More than 2000 different mutations in the LDLR gene have been found to cause FH (www.hgmd.cf.ac.uk; date last accessed January 20, 2017). These are commonly classified into five classes based upon their effects on the LDLR (5). Class 1 mutations prevent the synthesis of immunodetectable LDLR, and Class 2 mutations make the LDLR completely (Class 2a) or partially (Class 2b) retained in the endoplasmic reticulum (ER). Class 3 mutations make the LDLR defective in binding LDL, and Class 4 mutations prevent the LDLR from being concentrated in clathrin-coated pits. Class 5 mutations make the mutant LDLR unable to recycle after having internalized LDL. In addition, a sixth class of mutations has been proposed which affects residues of the transmembrane domain and prevents normal membrane insertion of the mutant LDLR (6, 7) .
We have previously reported that the naturally occurring mutations p.L799R (c.2396T > G) and p.G805R (c.2413G > A), which both introduce an arginine in the transmembrane domain of the LDLR, cause reduced number of cell membrane-bound LDLRs due to defective incorporation of the mutant LDLRs in the ER membrane (6, 7) . Thus, introduction of a positively charged residue in the hydrophobic core of the ER membrane may prevent proper membrane integration of the mutant LDLR from the Sec61 translocon channel (8) . However, whether these findings are restricted to certain positions within the transmembrane domain, remains to be determined. To further study the impact of charged residues in the transmembrane domain, we have mutated each of the 22 amino acids of the transmembrane domain to arginine.
Results
Effect of an arginine in the transmembrane domain of the LDLR HepG2 cells were transiently transfected with the wild-type (WT)-LDLR plasmid or one of the 22 mutant LDLR plasmids encoding mutant LDLRs where a residue of the transmembrane domain has been substituted with an arginine. Media and cell lysates from the transfected cells were subjected to Western blot analysis using an antibody against the N-terminal domain or the C-terminal HA tag, respectively (Fig. 1) .
In the media of cells transfected with the WT-LDLR plasmid, a 140 kDa ectodomain fragment was observed ( Fig. 1) which is in agreement with previous reports (6, 7) . In the lysates of these cells, the 160 kDa mature form and the 120 kDa precursor form of the LDLR were observed. In addition, a 140 kDa degradation product (D1-4-LDLR) where ligand-binding repeats 1-4 have been cleaved off (9) , and small amounts of a 17 kDa C-terminal membrane-bound fragment complementary to the 140 kDa ectodomain fragment in the media (10), were observed ( Fig. 1) .
In the media and lysates of cells transfected with mutant LDLR plasmids, varying amounts of the fragments found in the medium and lysate of cells transfected with the WT-LDLR plasmid, were observed (Fig. 1) . Generally, there was a gradual decrease in the total amounts of LDLRs both in the media and in the lysates, the more centrally in the transmembrane domain an arginine was located. Introducing an arginine in the outer part of the transmembrane domain at positions 789-791, or in the inner part at positions 806-810, did not markedly affect the amount of LDLRs in the media or in the lysates. In contrast, an arginine in positions 797-803 resulted in very low levels of LDLRs both in media and lysates (Fig. 1) .
As there were reduced amounts also of the 120 kDa precursor, these findings indicate that a basic residue in the center of the transmembrane domain prevents the synthesis of membrane-bound precursor LDLR in the ER. This will subsequently lead to reduced amounts of LDLRs in the cell membrane. To confirm these results, confocal laser-scanning microscopy was employed to demonstrate low amounts of the mutant L799R-LDLR in stably transfected CHO T-REx cells (Supplementary Material, Fig. S1 ). Moreover, these studies also showed that L799R-LDLR was predominantly located intracellularly rather than on the cell surface (Supplementary Material, S1 ). It should also be noticed that in the media of cells expressing the mutants L798R-LDLR or L799R-LDLR, faint bands representing the respective mature 160 kDa LDLR fragments were observed (Fig. 1) . Thus, small amounts of the entire LDLR including the cytoplasmic domain were secreted into the culture medium. Regarding L799R-LDLR, this observation is in agreement with a previous report where this 160 kDa fragment in the medium was detected by the use of a C-terminal antibody (7) .
To rule out the possibility that differences in transfection efficiencies were the explanation for the different amounts of mutant LDLRs, HepG2 cells were transiently transfected with a bicistronic plasmid expressing the green fluorescent protein together with the I796R-LDLR or L799R-LDLR mutants (Supplementary Material, Fig. S2 ). As the amounts of the green fluorescent protein in lysates were similar for the WT-LDLR and the two LDLR mutants, differences in the amounts of mutant and WT-LDLRs were not due to differences in transfection efficiencies.
Effect of replacing the transmembrane domain of the EGF receptor with that of I796R-LDLR or L799R-LDLR
To confirm that the reduced amounts of mutant LDLRs were actually due to the mutant residues in the transmembrane domain, the effect of substituting the transmembrane domain of the EGF receptor (EGFR) with that of the WT-LDLR, I796R-LDLR or L799R-LDLR, was studied. As can be seen from Figure 2 , markedly reduced amounts of the EGFR containing one of the two mutant LDLR transmembrane domains were observed in the lysates, as compared to that of the EGFR containing the WT-LDLR transmembrane domain. Moreover, significant amounts of the full-length EGFR containing the transmembrane domain of L799R-LDLR were found in the media (Fig. 2) . Thus, mutation p.L799R has a similar effect on the EGFR as on the LDLR. These data support the notion that it is the presence of a basic residue in the central part of the transmembrane domain which reduces the amount of membrane-bound LDLR.
Effect of an arginine in the transmembrane domain on c-secretase cleavage Ectodomain cleavage to release the 140 kDa ectodomain in the medium generates a membrane-bound 17 kDa C-terminal domain which undergoes c-secretase cleavage within the transmembrane domain (10) . The released cytoplasmic domain is then rapidly degraded. However, when c-secretase cleavage is inhibited by agents such as N-(N-(3,5-difluorophenacetyl)-L-alanyl)-S-phenylglycine t-butyl ester (DAPT), an increased amount of 17 kDa membrane-bound fragment is observed (10) . The failure to identify an increased amount of the 17 kDa fragment of a mutant LDLR in the presence of DAPT, indicates that the mutant LDLR is resistant to c-secretase cleavage.
For the mutants A789R-LDLR, L790R-LDLR and S791R-LDLR affecting residues from the outer part of the transmembrane domain and for mutants F807R-LDLR, L808R-LDLR, L809R-LDLR and W810R-LDLR affecting residues from the inner part of the transmembrane domain, increased amounts of the 17 kDa fragment were observed in the presence of DAPT which was similar to that of the WT-LDLR (Fig. 3) . Thus, these mutants appeared to undergo c-secretase cleavage in a normal fashion. For the mutants I792R-LDLR, L798R-LDLR, L804R-LDLR, G805R-LDLR and V806R-LDLR there were essentially no increased amounts of the respective 17 kDa fragments when the cells were cultured in the presence of DAPT (Fig. 3) . This indicates that an arginine at the respective positions in the transmembrane domain, prevents c-secretase cleavage. It may appear from the intensity of the 17 kDa fragment that residues 804-806 towards the inner part of the transmembrane domain are particularly important for c-secretase cleavage (Fig. 3) . Such cleavage close to the cytoplasm will promote effective release of the cytoplasmic domain for subsequent intracellular degradation.
Effect of an arginine in the transmembrane domain on metalloproteinase cleavage
For several of the mutant LDLRs the ratio between the amount of the 140 kDa ectodomain in the media and the membranebound 120 or 160 kDa forms in lysates, was different from that of the WT-LDLR (Fig. 1) . As ectodomain cleavage is caused by metalloproteinases (6, 11) , it is possible that the different mutants have different susceptibility to undergo metalloproteinase cleavage. Differences in the extent of ectodomain cleavage will manifest as differences in the amount of membrane-bound LDLRs in lysates. To study the extent of metalloproteinase cleavage of LDLR mutants with an arginine in the transmembrane domain, transfected HepG2 cells were cultured in the presence or absence of the metalloproteinase inhibitor batimastat (Fig. 4) .
For both the WT-LDLR and the mutant LDLRs, batimastat prevented ectodomain cleavage and increased the amounts of the 120 kDa precursor LDLR and the 160 kDa mature LDLR in lysates (Fig. 4) . However, for the mutants with centrally located arginines, batimastat failed to increase the levels of the respective precursor and mature LDLR to levels similar to that of the WT-LDLR. This indicates that the low levels of mutant LDLRs in lysates were not primarily due to increased propensity to metalloproteinase cleavage. However, for mutations V793R-LDLR, L804R-LDLR, G805R-LDLR and V806R-LDLR there appeared to be relatively higher amounts of the 140 kDa ectodomain fragment as compared to that of the WT-LDLR (Fig. 4) . These mutants may therefore have a somewhat increased susceptibility to metalloproteinase cleavage which may contribute to the reduced amounts of the respective 120 kDa precursor and 160 kDa mature forms in lysates.
Even though batimastat abolished ectodomain cleavage of mutants L804R-LDLR, G805R-LDLR and V806R-LDLR as determined by lack of the 140 kDa fragment in the media, only moderately reduced levels of the respective complementary C-terminal 17 kDa fragments were observed (Fig. 4) . Apparently, the underlying mechanism is the failure of these mutants to undergo c-secretase cleavage which makes these C-terminal fragments stable (Fig. 3) .
It should be noticed that for the mutant V806R-LDLR low amounts also of a shorter C-terminal fragment of 15 kDa, were observed in the lysate (Figs 1 and 4) . This fragment was not detected when the cells had been cultured in the presence of batimastat (Fig. 4) . Together, these data indicate that mutation p.V806R affects the structure of the LDLR such that a second metalloproteinase cleavage site is generated closer to the transmembrane domain. As a consequence, an additional shorter C-terminal fragment of 15 kDa is generated.
Does an LDLR with an arginine in the transmembrane domain undergo ER-associated degradation?
Another class of mutant LDLRs that present with low levels of cell-surface LDLRs due to intracellular degradation, is Class 2a mutants (5) . These mutants are folding-defective and undergo ER-associated degradation which involves ubiquitination of the cytoplasmic domain and subsequent proteasomal degradation (12, 13) . Studies were therefore performed to study whether ERassociated degradation was involved in degradation of mutant LDLRs with an arginine in the transmembrane domain. For these studies, the intracellular pattern of I796R-LDLR was compared to that of the Class 2a mutant G565V-LDLR in HepG2 cells transiently transfected with the respective plasmids. As can be seen from the Western blots in Figure 5 , there were markedly higher amounts of the 120 kDa fragment of the G565V-LDLR mutant as compared to that of the I796R-LDLR mutant. This finding indicates that the mechanism for the low levels of I796R-LDLR at the cell surface, is different from that of Class 2a mutants.
Furthermore, to study whether the mutants I796R-LDLR or L799R-LDLR induced ER stress, mRNA analysis of lysates from stably transfected CHO T-REx cells was assayed with respect to mRNA of the X-box binding protein 1 (XBP1) (Fig. 6) . The rationale for this assay is that ER stress leads to phosphorylation of inositol-requiring enzyme 1 which activates its endoribonuclease activity and causes skipping of 26 nucleotides in mRNA of XBP1 (14). 1,4-Dithiothreitol (DTT) was used as a positive control for ER stress. Whereas, no abnormal XBP1 mRNA was detected in cells transfected with the I796R-LDLR plasmid, skipping of the 26 nucleotides was observed in cells transfected with the L799R-LDLR plasmid (Fig. 6) . Thus, L799R-LDLR which is partly translocated to the hydrophilic ER lumen and has hydrophobic transmembrane residues exposed, causes ER stress. 
Studies on proteasomal or lysosomal degradation of mutant LDLRs
To study whether I796R-LDLR underwent proteasomal or lysosomal degradation, transfection experiments were performed in the presence of the proteasomal inhibitors lactacystin, epoxomicin or MG132, or in the presence of the lysosomal inhibitors leupeptin or ammonium chloride. Moreover, to study whether intracellular degradation required transport along microtubules, transfection experiments were also performed in the presence of nocadazole which disrupts the microtubules. As can be seen from Figure 7 , none of these inhibitors affected the amount of I796R-LDLR in lysates. The activity of the proteasomal inhibitors was demonstrated by their ability to increase the amount of p53 which undergoes proteasomal degradation (15) (Fig. 7) . Thus, the low amount of I796R-LDLR was not due to proteasomal or lysosomal degradation and was not due to degradation within an acidic compartment. Moreover, degradation did not require transport along microtubules. However, leupeptin and particularly MG132 increased the amount of the 17 kDa C-terminal fragment both for the WT-LDLR and I796R-LDLR (Fig. 7) . This finding could possibly reflect an inhibitory effect of these agents also on c-secretase activity.
Studies on autophagy of the mutant LDLRs
To study whether autophagy could be involved in degradation of the mutant LDLRs, confocal laser-scanning microscopy was performed to determine if L799R-LDLR co-localized with the autophagosome marker microtubule-associated protein 1A/1B- light chain 3 (LC3) (16) . However, no co-localization was observed (data not shown). Moreover, the reagents wortmannin and rapamycin which promote or inhibit autophagy, respectively (17), did not have an effect on the amount of L799R-LDLR (data not shown). Also, considering the failure of lysosomal inhibitors to rescue the amount of L799R-LDLR (Fig. 6) , it is unlikely that autophagy played a role in degradation of the mutant LDLRs. The cells were cultured in the presence or absence of lactacystin (10 lM), epoxomicin (1 lM), MG132 (10 lM), leupeptin (300 lM), ammonium chloride (NH4Cl) (10 mM) or nocodazole (20 lg/ml) for 24 h. Lysates and culture media were subjected to Western blot analysis using an antibody against the C-terminal HA-tag or against the ligand-binding domain, respectively. Molecular weight markers and the 160 kDa mature LDLR, a 140 kDa degradation product (D1-4-LDLR, lacking ligand-binding repeats 1-4) (9), the 120 kDa precursor LDLR and the 17 kDa C-terminal fragment are indicated. To demonstrate that the proteasomal inhibitors lactacystin and epoximicin were functional, the effect of these inhibitors on p53 which is known to undergo proteasomal degradation (15) , was included as a control. The amount of b-tubulin in the lysates was used as a loading control. One representative of three separate experiments is shown.
Discussion
In this study, we have performed a systematic screening of the effect of substituting the individual residues of the hydrophobic transmembrane domain of the LDLR, with the basic residue arginine. The aim was to study to what extent a charged residue in the transmembrane domain is tolerated, and to investigate the mechanism by which LDLRs with an untolerated charged residue are being disposed of. Moreover, the results of this study could provide important information regarding the pathogenicity of naturally occurring mutations within the transmembrane domain.
Our main finding was that the more centrally in the transmembrane domain an arginine was located, the lower amounts of both the 120 kDa precursor LDLR located in the ER and the 160 kDa mature LDLR located on the plasma membrane, were observed. These findings indicate that the underlying mechanism for the reduced amounts of cell-surface LDLR causing familial hypercholesterolemia, is diminished synthesis or increased degradation of the 120 kDa precursor form in the ER.
Mutations affecting the transmembrane domain should therefore be considered as a new sixth class of mutations causing familial hypercholesterolemia.
Normally, as the signal peptide of the LDLR emerges from the ribosome, it is recognized by the signal recognition particle (SRP) which binds to the SRP receptor on the ER membrane and delivers the nascent LDLR peptide to the Sec61 translocon complex (18, 19) . As translation continues, the emerging polypeptide is threaded through the translocon and the N-terminal domain is delivered into the ER lumen where a signal peptidase cleaves off the signal peptide. When the LDLR transmembrane segment reaches the ER membrane, the hydrophobic transmembrane helix is recognized and passed laterally into the lipid bilayer to make the LDLR membrane bound. As the C-terminal domain of the LDLR is subsequently translated, it remains as a cytosolic tail outside the ER membrane.
The LDLR transmembrane alpha-helix comprises 6 turns of amino acid residues with mainly hydrophobic side chains which shield the peptide backbone with its H-bond donor and acceptor groups against the strongly hydrophobic interior of the lipid membrane. During evolution of the LDLR in vertebrates, there has been a strong selection against charged residues within the transmembrane helix (6,7) as such residues would have reduced the stability of the helix in the membrane or inhibited its insertion in the lipid bilayer. With the exception of Pro 795 and Gly 805 there is little sequence conservation in the transmembrane domain (7) and it is tempting to speculate that Pro 795 and Gly 805 are conserved to give kinks and flexibility to the otherwise relatively rigid six-turn alpha helix (20) . These features may enable efficient membrane insertion from the translocon channel into the ER membrane.
There are all reasons to believe that the mechanism by which a basic residue in the hydrophobic transmembrane domain leads to reduced amounts of the ER-bound 120 kDa precursor, is that a charged residue interferes with insertion of the mutant LDLR in the ER membrane from the Sec61 translocon complex. As a charged residue in the outer or inner parts of the transmembrane domain to a lesser extent interfered with the amount of LDLR in lysates, it seems to be a requirement for a stretch of 17-19 hydrophobic residues for proper membrane insertion. An arginine in the transmembrane domain near the lipid bilayer surface may be tolerated due to the relatively long arginine side chain and snorkeling of the charged guanidinium group out of the hydrophobic core of the lipid bilayer (21).
The question then remains on the mechanism by which a mutant LDLR which is not inserted properly in ER membrane, is degraded. The most common mechanism for degradation of intracellular proteins involves proteasomal or lysosomal degradation (22) . However, the failure of proteasomal or lysosomal inhibitors to rescue the mutant LDLRs from degradation, indicates that lysosomal or proteasomal degradation were not involved. Moreover, the failure of inhibitors such as ammonium chloride or nocodazole to prevent degradation of the mutant LDLRs, indicates that an acidic compartment or transportation along microtubules were not involved in the degradation process. Furthermore, our data also indicate that autophagy did not play a role in degradation of the mutant LDLRs. Our data have also shown that the mechanism for degradation of the transmembrane mutants, was different from that of the Class 2a mutant G565V-LDLR which undergoes ER-associated degradation (12, 13) .
The low levels of the 120 kDa precursor of the mutant LDLRs, our failure to immunologically detect any major degradation products, and the failure to observe significant amounts of the full-length mutant LDLRs in the culture medium, indicate that the majority of the mutant LDLR is degraded shortly after synthesis or that the protein synthesis is less efficient. It is well known that cells have a ribosome quality control that dispose of polypeptides that are defective in folding or that are stalled at the ribosome due factors such as translation into the polyadenylation signal, or the failure to reach a stop codon because of defective mRNA (23) (24) (25) . This quality control involves ubiquitination and proteasomal degradation (24, 25) . However, the mechanism for degrading mutant transmembrane proteins that fail to be incorporated in the ER membrane, appears to be poorly understood.
In a study of proteins with different membrane topologies and artificially lacking a stop codon, it was shown that Emp47, which resembles the LDLR by having a large N-terminal domain, a transmembrane domain and a short C-terminal domain, was degraded by an ubiquitin-independent pathway (26) . These data indicated that the non-stop protein was not released from the ribosome and that this led to clogging of the Sec61 translocon. Based on their findings it is tempting to speculate that the failure of a mutant LDLR with an arginine in the central part of the transmembrane domain to be inserted in the ER membrane, may result in clogging of the Sec61 translocon. As a consequence, a quality control that recognizes stalled proteins in the Sec61 translocon could be activated. This quality control could be different from the ribosomal quality control that degrades cytosolic proteins stalled at the ribosome, as the latter involves proteasomal degradation.
However, it appears that other mechanisms may also contribute to degradation of these mutant LDLRs. For those mutants with an arginine in the very middle of the transmembrane domain, such as L798R-LDLR and L799R-LDLR, a minor proportion of the mutants were translocated into the ER lumen as illustrated by the presence of the respective full-length proteins in the culture media. In this case, hydrophobic residues of the transmembrane domain will be exposed to the hydrophilic milieu of the ER lumen and will generate ER stress, as was shown for L799R-LDLR. For some of the LDLR mutants, an increased propensity for ectodomain cleavage by metalloproteinases in the ER or at the cell membrane leading to increased secretion of the 140 kDa ectodomain, could also contribute to the low levels of the respective precursor and mature forms.
From our detailed analyses of possible mechanisms for degradation of mutant LDLRs with an arginine in the transmembrane domain, different mechanisms appear to be operating. However, the predominant mechanism appears to be rapid degradation at the level of ribosome/Sec61 translocon secondary to the failure of the mutants to be properly inserted into the ER membrane. Clogging of the Sec61 translocon channel by these mutants could possibly represent a signal for activation of such a degradation mechanism. However, further studies are needed to identify the features of such a proposed quality control.
Materials and Methods

Numbering of nucleotides and codons
Nucleotide numbering of the LDLR gene was based on the transcript NM_000527.4 with nucleotide #1 being the A of the ATG translation initiation codon. The translation initiation codon is codon #1.
Reagents
Batimastat was obtained from Calbiochem (Darmstadt, Germany). DAPT, epoxomicin, leupeptine, MG132, lactacystine, nocodazole and DTT were from Sigma-Aldrich Corp. (St. Louis, MO). All other reagents were standard laboratory reagents.
Cell cultures
HepG2 cells (European Collection of Cell Cultures, Wiltshire, UK) were cultured in Modified Eagle's medium (Gibco Life Technologies, Paisley, UK) containing 10% fetal bovine serum, 2 mM L-glutamine, 50 U/ml penicillin, 50 lg/ml streptomycin and non-essential amino acids. The cells were grown on collagencoated plates from BD Biosciences (San Jose, CA). CHO T-REx cells were cultured as previously described (27) .
Plasmids and transfections
Generation of the WT-LDLR plasmid containing a C-terminal HA tag has been previously described (7) . This plasmid was used as a template to mutate the individual residues of the transmembrane domain to arginines by using the QuickChange II XL Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. The WT-EGFR plasmid encoding the EGFR was a kind gift from Harald Stenmark (Centre for Cancer Biomedicine, University of Oslo). A chimeric EGFR-LDLR plasmid where the sequences encoding the transmembrane domain of the EGFR had been replaced by the sequences encoding the transmembrane domain of the LDLR, was constructed by sequential mutageneses of the WT-EGFR plasmid using QuickChange II XL Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. Because the transmembrane domain of the EGFR has 23 residues and that of the LDLR has 22 residues, Ile 646 of the EGFR transmembrane domain was retained in the chimeric EGFR/LDLR transmembrane domain and the following 22 residues of the EGFR transmembrane domain were replaced by the 22 residues of the LDLR transmembrane domain. The EGFR-LDLR plasmid was used as template to generate the EGFR-I796R-LDLR and EGFR-L799R-LDLR plasmids. The oligonucleotide sequences used for mutageneses are listed in Supplementary Material, Table S1 . The integrity of the plasmids was confirmed by DNA sequencing.
Transient transfection of HepG2 cells with HA-tagged LDLR plasmids was performed using FuGENE HD (Roche Diagnostics GmbH, Mannheim, Germany) as previously described (7). 24 h after transfection, the cells were washed and the medium was changed to Opti-MEM medium without phenol red (Gibco Life Technologies, Paisley, UK). After culturing for another 24 h, culture media were collected and lysates were prepared. CHO T-REx cells (Invitrogen, Carlsbad, CA) were stably transfected with the indicated plasmids and cultured as previously described (27) . These cells stably express a tetracycline repressor which makes it possible to induce gene expression by culturing the cells in the presence of tetracycline.
Western blot analysis
Western blot analyses of culture media (20 ll) or cell lysates (30 lg) were performed as previously described (6, 28) . A rabbit anti-HA antibody (Invitrogen, Carlsbad, CA) was used to detect the LDLR in lysates of transfected cells and a rabbit anti-LDLR antibody raised against the linker region between ligandbinding repeats 4 and 5 of the ligand-binding domain (Fitzgerald Industries International, Concord, MA), was used to detect ectodomain-cleaved LDLRs in the culture media. A sheep polyclonal anti-EGFR antibody (Fitzgerald Industries International, Concord, MA) was used to detect the EGFR and a mouse antip53 antibody (Santa Cruz Biotechnology, Dallas, TX) was used to detect p53. A rabbit polyclonal anti-b-tubulin antibody (Nordic Biosite AB, T€ aby, Sweden) was used to detect b-tubulin which was used as a loading control.
RT-PCR analysis of XBP1 splicing to identify ER stress
Total RNA was isolated from CHO T-REx cells stably transfected with the WT-LDLR plasmid or a mutant LDLR plasmid using QIAamp RNA Blood Mini Kit (Qiagen, Hilden, Germany). One microgram of RNA was reverse-transcribed using Qiagen Onestep RT-PCR kit (Qiagen, Hilden, Germany) and primers amplifying XBP1 mRNA (Supplementary Material, Table S1 ). The reverse transcription reaction was run at 50 C for 30 min. PCR cycling conditions included a 15 min polymerase activation step at 95 C, followed by 40 cycles of 1 min denaturation at 94 C, 1 min annealing at 60 C and 1 min extension at 72 C. PCR products were subjected to electrophoresis on a 2% agarose gel at 50V for 240 min and stained with GelRed Nucleic Acid Gel Stain (Biotium, Inc., Fremont, CA). RNA isolated from CHO T-REx cells treated with 5 mM DTT for 24 h was used as a positive control for ER stress.
